CYDY
EquityCytoDyn Inc.
Health Care · Biotechnology
$0.25
+0.25 (+0.00%)
Open
N/A
Day Range
$0.24 - $0.25
52W Range
$0.19 - $0.45
Volume
440K
Price History
Key Statistics
Market Cap
N/A
P/E Ratio
N/A
EPS
N/A
Dividend Yield
N/A
P/B Ratio
N/A
Payout Ratio
N/A
ROE
N/A
Debt/Equity
N/A
Institutional Ownership
| Holder | Shares | % Held | Value |
|---|---|---|---|
| Nbc Securities, Inc. | 160,000 | 0.01% | $39.8K |
| Diversified Trust Company | 45,790 | 0.00% | $11.4K |
| Williams Jones Wealth Management, LLC. | 45,001 | 0.00% | $11.2K |
| Next Capital Management, LLC | 32,500 | 0.00% | $8.1K |
| Horizon Financial Services, LLC | 18,200 | 0.00% | $4.5K |
| Northstar Asset Management Co. | 10,000 | 0.00% | $2.5K |
| Ancora Advisors, LLC | 9,488 | 0.00% | $2.4K |
| Caz Investments LP | 4,000 | 0.00% | $995.0 |
Latest News
CytoDyn Presents Novel CCR5 Inhibition Mechanisms and Long-Term Survival Signals for Leronlimab in Metastatic Breast Cancer at AACR Immuno-Oncology Conference
CytoDyn Announces Funding and Initiation of Expanded Access Program for Patients with Triple-negative Breast Cancer
December 2025 Letter to Shareholders
CytoDyn to Showcase PD-L1 Upregulation and Improved Survival in Metastatic Triple Negative Breast Cancer at the San Antonio Breast Cancer Symposium
CytoDyn Announces Resolution of Class Action Lawsuit
Peers in Health Care
| Symbol | Name | Price | Mkt Cap | Div Yield | Change |
|---|---|---|---|---|---|
| ABCL | AbCellera Biologics Inc. | $3.61 | N/A | - | +0.00% |
| ABUS | Arbutus Biopharma Corporation | $4.66 | N/A | - | +0.00% |
| 001540.KQ | AHN-GOOK PHA | $8,070.00 | N/A | 5.45% | +0.00% |
| AHCO | AdaptHealth Corp. | $9.15 | N/A | - | +0.00% |
| AKBA | Akebia Therapeutics, Inc. | $1.31 | N/A | - | +0.00% |
| ABBV | AbbVie Inc. | $232.08 | N/A | 2.87% | +0.00% |
| ACAD | ACADIA Pharmaceuticals Inc. | $24.56 | N/A | - | +0.00% |
| CRSP | CRISPR Therapeutics AG | $60.14 | N/A | - | +0.00% |
About CytoDyn Inc.
CytoDyn Inc., a clinical-stage biotechnology company, develops treatments for multiple therapeutic indications. It is involved in the clinical development of leronlimab, a novel humanized monoclonal antibody targeting the C-C chemokine receptor type 5 receptor in the areas of COVID-19. The company's leronlimab is currently under phase 2 development for the treatment of micro-satellite stable colorectal cancer, and solid tumors in oncology, such as metastatic triple-negative breast cancer. The company was formerly known as RexRay Corporation. CytoDyn Inc. was incorporated in 2002 and is based in Vancouver, Washington.
www.cytodyn.com →Dividend Safety
Assessment based on payout ratio, debt levels, profit margins, and dividend growth track record.
Borderline
Based on 4 fundamental factors
Analysis Tools
Share
No dividend data available for CYDY
Dividend Safety
Assessment based on payout ratio, debt levels, profit margins, and dividend growth track record.
Borderline
Based on 4 fundamental factors
Loading financial data...
Revenue & Earnings
No financial statement data available for CYDY.